Core Scientific Inc's next confirmed earnings release is scheduled for November 5, 2026.
| Earnings Date | 11/5/2026 |
As of June 30, 2026, Core Scientific Inc has 319.59M shares outstanding.
| Shares Outstanding | 319.59M |
As of June 30, 2026, Core Scientific Inc maintains a current ratio of 0.89, meaning it holds 0.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -177.65, indicating conservative leverage, while an interest coverage ratio of -103.95 demonstrates limited ability to service its debt obligations.
| Current Ratio | 0.89 |
| Quick Ratio | 0.79 |
| Debt / Equity | -177.65 |
| Debt / EBITDA | -8.51 |
| Interest Coverage | -103.95 |
These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -39.59, reflecting losses generated across the asset base. The company generates approximately 1.19M in revenue per employee across its workforce of 325.00, a quick read on workforce productivity versus industry peers.
| Return on Assets (ROA) | -39.59 |
| Revenue Per Employee | 1.19M |
| Employee Count | 325.00 |
Over the twelve months ended June 30, 2026, Core Scientific Inc recorded 2.39M in income tax expense. The company reported a pretax loss of -1.25B and -1.25B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.
| Income Tax | 2.39M |
Over the twelve months ended June 30, 2026, Core Scientific Inc generated 385.40M in revenue and converted that into -1.25B in net income, yielding earnings per share of -3.50. EBITDA reached -441.92M, while operating income came in at -180.22M.
| Revenue | 385.40M |
| Gross Profit | 109.25M |
| Operating Income | -180.22M |
| Pretax Income | -1.25B |
| Net Income | -1.25B |
| EBITDA | -441.92M |
| EBIT | -507.43M |
| Earnings Per Share (EPS) | -3.50 |
As of June 30, 2026, Core Scientific Inc holds 1.55B in cash and equivalents against 3.76B in total debt, resulting in a net debt position of 2.21B. Total book value stands at -2.12B, with working capital of -257.47M providing operational flexibility.
| Cash & Cash Equivalents | 1.55B |
| Total Debt | 3.76B |
| Net Debt | 2.21B |
| Equity (Book Value) | -2.12B |
| Book Value Per Share | -6.63 |
| Working Capital | -257.47M |
Core Scientific Inc produced 451.48M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -1.30B in capital expenditures, free cash flow totaled -847.27M - equivalent to -2.63 per share.
| Operating Cash Flow | 451.48M |
| Capital Expenditures | -1.30B |
| Free Cash Flow | -847.27M |
| FCF Per Share | -2.63 |
Over the twelve months ended June 30, 2026, Core Scientific Inc posted a gross margin of 28.35, reflecting its pricing power and cost economics. The operating margin of -46.76 and net profit margin of -325.31 provide insight into operational efficiency.
| Gross Margin | 28.35 |
| Operating Margin | -46.76 |
| Pretax Margin | -324.69 |
| Profit Margin | -325.31 |
| EBITDA Margin | -114.67 |